Edge of scotoma sensitivity as a microperimetry clinical trial end point in ush2a retinopathy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: Microperimetry is commonly used to assess retinal function. We perform cross-sectional and longitudinal analysis on microperimetry parameters in USH2A retinopathy and explore end points suitable for future clinical trials. Methods: Microperimetry was performed using two grids, Grid 1 (18° diameter) and Grid 2 (6° diameter). In Grid 1, four parameters (number of nonscotomatous loci, mean sensitivity [MS], responding point sensitivity [RPS], and edge of scotoma sensitivity [ESS]) were analyzed. In Grid 2, number of nonscotomatous loci and MS were examined. Interocular symmetry was also examined. Longitudinal analysis was conducted in a subset of eyes. Results: Microperimetry could be performed in 16 of 21 patients. In Grid 1 (n = 15; average age, 35.6 years), average number of nonscotomatous loci, MS, RPS, and ESS were 46.6 loci, 10.0 dB, 14.7 and 9.6 dB, respectively. In Grid 2 (n = 13; average age, 37.4 years), 12 eyes had measurable sensitivity across the entire grid. Average MS was 23.8 dB. Interocular analysis revealed large 95% confidence intervals for all parameters. Longitudinally, Grid 1 (n = 12, average follow-up 2.6 years) ESS showed the fastest rate of decline (–1.84 dB/y) compared with MS (–0.34 dB/y) and RPS (–0.90 dB/y). Conclusions: Our data suggest that ESS may be more useful than MS and RPS in test grids that cover a large extent of the macula. We caution the use of contralateral eye as an internal control. Translational Relevance: ESS may decrease the duration or sample size of treatment trials in USH2A retinopathy.

Original languageEnglish
Article number9
Pages (from-to)1-13
Number of pages13
JournalTranslational Vision Science and Technology
Volume9
Issue number10
DOIs
Publication statusPublished - Sep 2020

Fingerprint Dive into the research topics of 'Edge of scotoma sensitivity as a microperimetry clinical trial end point in ush2a retinopathy'. Together they form a unique fingerprint.

Cite this